BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert - 2Instructions to Construct an Organization While Chasing after a Web-based Degree
- 3A definitive Manual for the 5 Off-road Bicycles Available
- 4A Couple of Modest Guitars for 2024
- 5Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.
- Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- The most effective method to Decisively Use Open Record Rewards
- Vote In favor of Your Number one Kind Of Food Conveyance Administration
- Heartfelt Objections to Visit with Your Adored One
- New Jordan security fence could be done in early 2028
- How food assistance programs can feed families and nourish their dignity
- Language Learning Stages: Which One Gets Your Vote?
- 6 Exemplary Mexican Dishes
- Top 5 Top of the line Books of the Year
